SVB Leerink Initiates Coverage On NovoCure with Outperform Rating, Announces Price Target of $51
Portfolio Pulse from richadhand@benzinga.com
SVB Leerink analyst Jonathan Chang has initiated coverage on NovoCure (NASDAQ:NVCR) with an Outperform rating and a price target of $51.
August 04, 2023 | 3:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NovoCure has been given an Outperform rating and a price target of $51 by SVB Leerink.
The Outperform rating from SVB Leerink indicates that the analyst expects NovoCure to do better than the market average. This positive outlook, coupled with a price target of $51, suggests potential upside for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100